Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke (CLEAR Stroke) Trial

X
Trial Profile

Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke (CLEAR Stroke) Trial

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Apr 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alteplase (Primary) ; Eptifibatide (Primary)
  • Indications Embolism and thrombosis; Stroke
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CLEAR
  • Most Recent Events

    • 19 Feb 2016 Results of pooled analysis (n=247) of this and other 2 trials (CLEAR-ER and CLEAR-FDR) presented at the 41st International Stroke Conference
    • 01 Dec 2008 Primary endpoint results published in Stroke 39: 3268-3276, No. 12, Dec 2008
    • 06 Dec 2007 Status changed from in progress to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top